Followers | 20 |
Posts | 5392 |
Boards Moderated | 0 |
Alias Born | 01/04/2012 |
![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Sunday, February 11, 2018 1:38:25 PM
Since the breast cancer reduction discovery only surfaced in 2015, it is indicative of one of the following scenarios.
1- ANIP did the analysis of the pre-marketing part of the Libigel study and made the discovery. However, if this were the case the specifications and details supporting the claim would have been included in the patent application. It would serve no purpose and actually would be detrimental to advancing the patent application to purposely withhold the information, as the patent application presently stands.
2- ANIP did the pre-marketing analysis and continued the study thereby making the December 2015 discovery. The R&D expenses for ANIP do not support their continuing the trial to make this discovery. Once again if it was their discovery they would properly supported the claims. Since it was not done it is highly unlikely they made the discovery.
3- A silent partner such as AbbVie, did the pre-marketing analysis and made the discovery the breast cancer reduction discovery. However if the breast cancer discovery had materialized earlier we would have seen the claims added earlier. Otherwise, they risk someone else slipping in ahead of them and claiming prior art. Not a risk worth taking. Therefore it is likely that they also continued the safety/efficacy trial and made the discovery upon the continuation of the trial.
Now if the study was not continued, any future partner would have to start a large testosterone trial from scratch. The FDA is sill going to want 5 years of continuous use safety data. Not continuing the trials essentially wastes 7300 patient years of study. The 70% CV risk reduction discovery at 4000 patient years de-risk the continuation of the trial. Had BPAX publicly advertised these findings and were truly looking a for a partner they would have had many offers by large pharma to continue the trial.
The logical move was to continue the trial and have the partner take it the rest of the way. The fact that Dr Snabes worked for both AbbVie and Bisoante at the same time and was later hired full time by AbbVie, in addition to contracting IT work to Pat Fuller is consistent with a tech transfer of Libigel to AbbVie in order for Dr Snabes to continue the study.
Something to consider when Biosante completed their part of the study non of the patients would have had complete 4 years of follow up. By December 2015 the majority of patients would have completed the 5 years of follow up.
In 2013 Przybyl admitted that his eventual goal was to get a co-promotion deal for Libigel. The fact that no announcement of a partnership has been announced while evidence supports the existence of a partnership, is most likely a condition placed on them by the partner. This allowed the partner time to decide whether to acquire ANIP or partner on Libigel without ANIP attracting hostile take over action.
JMHO
Recent ANIP News
- ANI Pharmaceuticals Announces the FDA Approval and Launch of Naproxen Delayed-Release Tablets, USP • GlobeNewswire Inc. • 07/02/2024 11:00:00 AM
- ANI Pharmaceuticals’ CEO Nikhil Lalwani Named EY Entrepreneur Of The Year® 2024 New Jersey Award Winner • GlobeNewswire Inc. • 06/25/2024 11:00:02 AM
- ANI Pharmaceuticals to Further Expand Rare Disease Business through Acquisition of Alimera Sciences • GlobeNewswire Inc. • 06/24/2024 10:50:44 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/18/2024 08:37:33 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/17/2024 09:05:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 09:23:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/11/2024 08:51:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 10:21:47 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 11:34:13 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/05/2024 11:59:24 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/04/2024 10:08:03 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/04/2024 08:35:27 PM
- ANI Pharmaceuticals to Present at the 2024 Jefferies Global Healthcare Conference • GlobeNewswire Inc. • 05/29/2024 08:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/24/2024 12:03:53 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/24/2024 12:02:18 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/23/2024 11:58:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/23/2024 11:54:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/23/2024 11:45:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/23/2024 08:06:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 10:14:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/21/2024 09:21:53 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/20/2024 08:57:32 PM
- ANI Pharmaceuticals Announces the Launch of Kionex® Suspension • GlobeNewswire Inc. • 05/20/2024 10:50:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 10:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 10:01:01 PM
FEATURED Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM